271. Ankylosing spondylitis Clinical trials / Disease details

Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01649375 (ClinicalTrials.gov)	October 18, 2012	20/7/2012	16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis	A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis	Anklyosing Spondylitis	Drug: Secukinumab (75 mg);Drug: Placebo;Drug: Secukinumab (150 mg)	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	219	Phase 3	United States;Austria;Canada;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;Czech Republic
2	NCT01358175 (ClinicalTrials.gov)	October 2011	19/5/2011	16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: Secukinumab (75 mg);Drug: Secukinumab (150 mg);Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	371	Phase 3	United States;Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom